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Title of Project: Eliciting Autoimmunity to Ovarian Tumors in Mice by Genetic Disruption of T Cell Tolerance Mechanisms
Please note: This document represents an update of our "final" report from 2006. The new data obtained in 2007 is presented in a section entitled "Recent Results, March 2007", which comes after Aim 3. We thought it would be more convenient for the reviewers to have all the information in one document.
Introduction:
Research in the fields of basic immunology and autoimmunity has identified several distinct mechanisms through which immune tolerance is established and maintained in the normal host, and additional mechanisms will likely be identified in future. We hypothesize that ovarian tumors are recognized in an antigen-specific manner by T cells but induce immunologic tolerance through one or more of these homeostatic mechanisms, which have evolved to protect the host from autoimmune attack. We further hypothesize that tolerance to ovarian tumors can be overcome by disrupting critical components of tolerogenic pathways through genetic manipulation of T cells. To test this hypothesis, we proposed to develop a murine model for ovarian cancer that will allow, for the first time, precise monitoring of the functional responses of naïve, tumor-specific CD4+ and CD8+ T cell clones to ovarian tumors. Multiple properties of tumor-reactive T cells will be assessed in vivo, including their localization, activation, anergic status, proliferation and apoptosis. Differential responses and anti-tumor activities of the CD4+ and CD8+ T cell subsets will be investigated. Finally, the model will be used to evaluate the functional responses of tumor-specific CD4+ and CD8+ T cells that are genetically pre-disposed to autoimmune activity. The first tolerogenic pathway tested will be that involving the Cbl-b gene, as T cells lacking Cbl-b have a greatly reduced requirement for CD28 co-stimulation and demonstrate hyperactivity in vivo with profound autoimmune sequelae. The specific aims of this proposal are: Aim 1. To generate an ovarian tumor cell line that is recognized by antigen-specific CD4+ and CD8+ T cell clones from TCR transgenic mice. Aim 2. To define the mechanisms by which ID8 ovarian tumors evade rejection by tumorspecific CD4+ and CD8+ T cells. Aim 3. To determine whether tumor-specific CD4+ and CD8+ T cells lacking the Cbl-b gene show enhanced functional responses to ovarian tumors.
Body:
Aim 1: To generate an ovarian tumor cell line that is recognized by antigen-specific CD4+ and CD8+ T cell clones from TCR transgenic mice.
As described in the previous progress report, we had to generate a more aggressive ovarian tumor cell line for our experiments, as we encountered problems with spontaneous rejection of the original ID8 cell line when it was made to express epitope-tagged neu (neu OT-I/OT-II ). We generated a more aggressive subclone by serial transplantation of ID8 cells in syngeneic host mice. The new subclone (ID8-G7) induces tumors in just 30-40 days, as opposed to the 120-day latency of the original ID8 cell line. We have successfully transfected the new subclone with the neu OT-I/OT-II construct under the control of the β-actin promoter (ID8-NOO) and achieved stable expression (Figure 1) To investigate how large an OT-I T cell population was required to induce tumour regression, we reduced the dose of OT-I cells to 6 x 10 6 or 1 x 10 6 . Donor T cells still underwent activation, proliferation and infiltration of the peritoneal cavity and tumor site ( Figure 3 ). However, tumor regressions were never observed at these lower T cell doses (Table 1) . In principle, if 6 x 10 6 T cells were to undergo only 1 additional round of proliferation, they could theoretically reach equivalent numbers as achieved with the 1 x 10 7 dose. This lead us to question what factors may limit the expansion or persistence of CD8+ T cells in the ovarian tumour microenvironment.
In this regard, we observed that activated OT-I T cells express CD25 (the alpha subunit of the IL-2 receptor) when they infiltrate ovarian tumors, yet are CD25-negative in blood, lymph node and ascites (Figure 4 and data not shown). This suggests that OT-I cells may undergo local, IL-2-induced proliferation within the tumour bed, which may be an important determinant of the final population size. Indeed, OT-I T cells rendered genetically deficient for the IL-2 receptor beta subunit show reduced numbers in ascites after adoptive transfer into tumourbearing hosts ( Figure 5 ). Similar results were seen with OT-I cells rendered genetically deficient for the IL-2 receptor alpha chain (not shown). This indicates IL-2 signaling plays an important role in sustaining antigen-specific T cell proliferation and tumor cell killing.
Finally, we investigated whether the massive proliferative response demonstrated by OT-I cells in response to ovarian tumours required antigen-expression by the tumour, or whether it was driven non-specifically by cytokines in the tumour microenvironment. OT-I cells were co-transferred with an equal number of CD8+ P14 cells, which express a T cell receptor specific for an antigen not present in the tumour (gp33 from LCMV). P14 cells were activated by subcutaneous immunization with cognate antigen (gp33 peptide). Although they mounted a normal proliferative response in blood (Fig. 6A ), P14 cells failed to achieve the exceptionally high numbers seen with OT-I cells in blood, ascites or solid tumour nodules (Fig. 6A, B) . Thus, the massive proliferation and accumulation of OT-I cells is not only triggered by antigen in draining lymph nodes, but requires re-encounter with antigen at the tumour site as well. This suggests that effective eradication of ovarian tumours depends on antigen-and IL-2-driven CD8+ T cell proliferation at the tumour site.
Aim 3: To determine whether tumor-specific CD4+ and CD8+ T cells lacking the Cbl-b gene show enhanced functional responses to ovarian tumors.
As described in previous progress reports, the Cbl-b -/-mice we received from Dr. Josef Penninger's lab were not on a pure B6 background. Therefore, we have had to backcross the mice onto the B6 background. We completed 10 generations of backcrossing to obtain Cbl-b deficient OT-I cells on a pure C57Bl6 background. To date, we have performed one experiment in which these cells (1 x 10 7 ) were adoptively transferred into wild type mice bearing ID8-G7 ovarian tumours. Compared to wild-type OT-I cells, Cbl-b-deficient OT-I cells mounted a 25-50% greater proliferative response in peripheral blood, which was followed by tumour regression in all cases. This supports our hypothesis that CD8+ T cells lacking the Cbl-b gene show enhanced functional responses to ovarian tumors. Current experiments are determining Cbl-b-deficient OT-I cells outperform wild type OT-I cells when infused at limiting doses (i.e., 1 x 10 6 cells). In the near future, we will test the functional activity of Cbl-b-deficient CD4+ OT-II cells in our model.
Recent studies (March 2007)
As described above in Aim 2, OT-I cells underwent a massive proliferative response in mice bearing advanced ovarian tumours. This was unexpected, since ascites is thought to represent an immunosuppressive environment. To explore this further, we isolated ascites from tumour-bearing mice and assessed whether it promoted or inhibited T cell proliferation when added to an in vitro proliferative assay. First, we tested the effects of ascites using the murine CD8+ T cell line CTLL-2, which proliferates strongly in response to IL-2. Ascites alone did not induce CTLL-2 proliferation, indicating that it did not contain any growth factors such as IL-2 or IL-15 (Figure 7) . However, to our surprise, ascites was able to markedly enhance the proliferative response induced by IL-2 (Figure 7 ). This effect was seen even when we used a concentration of ascites as low as 0.25% (data not shown). Therefore, the factor that mediates this effect is either very potent, or it is present at a high concentration. Similar results were seen with primary CD8+ T cells, namely the P14 cells described above (Figure 8 ). In summary, ascites from ID8 ovarian tumours contains an unidentified factor that potently enhances T cell proliferation. This may explain the massive T cell proliferation seen in this model, and the subsequent tumour regressions. We hypothesize that this factor is a cytokine or other growth factor. Currently, we are using a candidate approach to try to identify this factor. In addition, we are determining whether ascites from human ovarian cancer patients has the same activity. Even if this factor is not present in human ovarian cancer, it may prove to be a useful immunomodulatory agent for enhancing the immune response against ovarian cancer, and possibly other cancers as well.
Key Research Accomplishments:
The following items have been completed or are underway: 
Conclusions:
We have created a novel mouse model for ovarian cancer that allows precise analysis of CD4+ and CD8+ T cell responses in the tumour microenvironment. After adoptive transfer, CD8+ OT-I T cells undergo massive proliferation in response to ovarian tumours, and are able to induce tumor regression in a dose-dependent manner. This response is dependent on both IL-2 signaling and re-encounter with antigen at the tumour site. Furthermore, there appears to be a factor in ascites that enhances T cell proliferation, which may explain the massive T cell response. Genetic deletion of the negative regulator Cbl-b from OT-I cells leads to an enhanced proliferative response, which is followed by tumour regression. Current studies are investigating whether Cbl-b-deficient OT-I cells outperform wild type OT-I cells by inducing tumour regression at limiting cell doses. If so, then genetic manipulation of human CD8+ T cells to disrupt Cbl-b function may represent an attractive, novel approach to enhancing the efficacy of T cell therapy against ovarian cancer.
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Appendices:
See accompanying Figures 1-8 OT-I cells were co-transferred with an equal number of CD8+ P14 cells, which express a T cell receptor specific for an antigen not present in the tumour (gp33 from LCMV). P14 cells were activated by immunization with cognate antigen (gp33 peptide). Although they proliferated in blood (panel A), they failed to achieve the high numbers seen with OT-I cells in blood, ascites or tumour nodules (panels A and B). Figure 8 . Ascites from ovarian tumour-bearing mice synergizes with antigen stimulation to promote the proliferation of primary CD8+ T cells from P14 TCR transgenic mice. Bromodeoxyuridine (BrdU) incorporation by P14 cells stimulated for 48h with cognate gp33 peptide in the presence (red) or absence (blue) of 1% ascites from an ID8-G7 tumour-bearing mouse. 
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